Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia

Pregnant women who were exposed to artemether-lumefantrine (AL) for the treatment of uncomplicated malaria were followed up and evaluated in a prospective cohort study. This report assessed the longitudinal safety outcomes of the pregnant women inadvertently exposed during the first trimester. Exposure was not associated with particular safety risks, suggesting that randomized clinical trials could now be the way forward to assess safety and efficacy of ACT in the first trimester of pregnancy.

← Back to previous page